Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction. [PDF]
Drug Des Devel Ther, 2016 Marilita M Moschos, Eirini Nitoda 1st Department of Ophthalmology, Medical School, National & Kapodistrian University of Athens, Athens, Greece Aim: The aim of this review was to summarize the ocular action of the most common phosphodiesterase (PDE)
Moschos MM, Nitoda E.
europepmc +3 more sources
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19? [PDF]
Int J Mol Sci, 2020 In March 2020, the World Health Organization declared the severe acute respiratory syndrome corona virus 2 (SARS-CoV2) infection to be a pandemic disease. SARS-CoV2 was first identified in China and, despite the restrictive measures adopted, the epidemic
Giorgi M +7 more
europepmc +2 more sources
Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist. [PDF]
ACS Chem Neurosci, 2020 Increasing human life expectancy prompts the development of novel remedies for cognitive decline: 44 million people worldwide are affected by dementia, and this number is predicted to triple by 2050.
Ribaudo G +4 more
europepmc +2 more sources
Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale. [PDF]
J Alzheimers Dis Rep, 2020 Background: Preclinical studies, clinical trials, and reviews suggest increasing 3’,5’-cyclic adenosine monophosphate (cAMP) and 3’,5’-cyclic guanosine monophosphate (cGMP) with phosphodiesterase inhibitors is disease-modifying in Alzheimer’s disease (AD)
Sanders O, Rajagopal L.
europepmc +2 more sources
Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19). [PDF]
Cureus, 2020 Effective treatments for Coronavirus Disease 2019 (COVID-19) outbreak are urgently needed. While anti-viral approaches and vaccines are being considered immediate countermeasures are unavailable. The aim of this article is to outline a perspective on the
Solaimanzadeh I.
europepmc +2 more sources
New Avenues for Phosphodiesterase Inhibitors in Asthma. [PDF]
J Exp Pharmacol, 2021 Maria Gabriella Matera,1 Josuel Ora,2 Francesco Cavalli,2 Paola Rogliani,2,3 Mario Cazzola3 1Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Respiratory Diseases Unit, “Tor Vergata&rdquo ...
Matera MG +4 more
europepmc +2 more sources
Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer. [PDF]
J Cancer, 2017 Purpose: Lung cancer remains the leading cause of cancer-related deaths worldwide and novel therapeutic approaches targeting crucial pathways are urgently needed to improve its treatment.
Domvri K +7 more
europepmc +2 more sources
Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair. [PDF]
Int J Mol Sci, 2017 A wide diversity of perturbations of the central nervous system (CNS) result in structural damage to the neuroarchitecture and cellular defects, which in turn are accompanied by neurological dysfunction and abortive endogenous neurorepair.
Knott EP +4 more
europepmc +2 more sources
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. [PDF]
BioDrugs, 2015 Phosphodiesterase (PDE) 4 participates in regulating the inflammatory response by degrading cyclic adenosine 3′,5′-monophosphate (cAMP), a key second messenger.
Gooderham M, Papp K.
europepmc +2 more sources
Phosphodiesterase inhibitors as therapeutics for traumatic brain injury. [PDF]
Curr Pharm Des, 2015 Developing therapeutics for traumatic brain injury remains a challenge for all stages of recovery. The pathological features of traumatic brain injury are diverse, and it remains an obstacle to be able to target the wide range of pathologies that vary ...
Titus DJ +3 more
europepmc +2 more sources